Ex-Billionaire Shivinder Singh Sues Brother as Empire Collapses
(Bloomberg) -- The unraveling of one of India's most storied business empires has caused a rupture in its founding family, with one of the Singh brothers -- synonymous with each other for decades -- saying he has sued the other for alleged "oppression and mismanagement" of their companies.
In a statement, Shivinder Singh said he filed a case with India's National Company Law Tribunal against his elder brother Malvinder and Sunil Godhwani, former chairman of Religare Enterprises Ltd., the financial services company the brothers used to control. Shivinder alleges Malvinder and Godhwani were to blame for “a systematic undermining of the interests of the companies and their shareholders.” Malvinder, 45, and Godhwani couldn't be reached for comment.
“I am now disassociating from my brother as a business partner and will be pursuing an independent path going forward,” Shivinder, 43, wrote in the statement dated Sept. 4. "I can no longer be party to activities in which transparency and ethics are continuously and consistently negated." Bloomberg News couldn't immediately obtain the case filing from the tribunal, which couldn't be reached.
Heirs to a generations-old business house once worth billions, the brothers have in recent months seen a dramatic fall in their fortunes. They've had their public shareholdings seized by lenders, and are under a criminal probe by financial authorities over 23 billion rupees ($321 million) missing from their listed companies. They owe $500 million over fraud allegations related to the 2008 sale of drugmaker Ranbaxy Laboratories.
The brothers have previously denied any wrongdoing.
Healthcare Empire
Last month, Bloomberg News published a story detailing the business linkages between the brothers and Gurinder Singh Dhillon, the head of a spiritual sect in North India called the Radha Soami Satsang Beas. These included loans to Dhillon's family and companies controlled by them, which Bloomberg's investigation found to be a key financial strain on their empire. Dhillon hasn't been accused of any wrongdoing.
Shivinder in the statement said he filed the case against his brother and Godhwani after media articles.
"Attempts to pass the buck to an eminent figure, who has been a guiding light not only to our family but also to a large section of the public, deceives no one," Shivinder wrote. He also said Malvinder was chairman of their corporate group and took decisions on behalf of the family, while he was "the publicly supportive younger brother."
For more, read: The Billionaires and the Guru: A Family Burns Through $2 Billion
The Singhs are famous in India for expanding their two public firms -- hospital operator Fortis Healthcare Ltd. and financial firm Religare -- at breakneck speed after reaping $2 billion from the sale of Ranbaxy, then India's largest drugmaker. Both companies went on to top $1 billion in market value as India's demand for health and financial services surged.
India's stock market and fraud regulators have launched investigations into financial irregularities at Religare and Fortis, although they are yet to report their findings. In July Malaysia's IHH Healthcare Bhd agreed to take control of Fortis and minority shareholders have taken over at Religare.
The Singhs resigned from their posts at Fortis in February. They've lost almost all their shareholdings in both Fortis and Religare as their lenders called in unpaid debts.
To contact the reporter on this story: Ari Altstedter in Mumbai at aaltstedter@bloomberg.net
To contact the editors responsible for this story: K. Oanh Ha at oha3@bloomberg.net, Anjali Cordeiro, Jeff Sutherland
©2018 Bloomberg L.P.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.
-
It's Time To Take The GST Council's Bet On Trust Global
Payment records can prove India's services exports, and clear, proportionate rules can bring foreign digital sellers into the tax net.
-
Opinion | India at 38: From Innovation Overperformer to Innovation Powerhouse
India now has 453 VC-backed deep science startups, 18 of them late-stage, after 117 percent growth since 2020. Laurus Labs, at USD 9.3 billion, is the most valuable deep science company in any middle-income economy outside China.
-
Navigating Energy Crossroads: S Jaishankar's Call For Diversified Supply Chains At G20 Ministerial Meeting
As geopolitical fault lines continue to test maritime trade routes and commodity flows, Jaishankar's message remains pertinent: true economic resilience requires open markets, protected transit lines, and a genuine commitment to multilateral cooperation rather than coercion.
-
Indians Are Travelling, But Not Every Journey Is A Holiday | The Week In Whys
Pilgrims, patients and working women are the real travellers, and the system hasn't quite caught up with them.
-
Getting To Work Costs Women More | The Reason Why
It is not just about women paying more than men. It is about women paying much more in cities than in villages.